Manon Evans

Evaluating tsunami risk perception and preparedness of people and institutions in the town of Siracusa, Italy

Filippo Zaniboni, Stefano Tinti, Delphine Grancher, Lydie Goeldner‐Gianella et autres

Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer

Steven Ades, Shailesh Kumar, Murad Alam, Annabel Goodwin et autres

us (code pays fourni par la source)

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial

Manon Evans, Ryan D. Guest, Dominic G. Rothwell, Debbie Burt et autres

Meeting abstracts Management of advanced B cell malignancies refractory to standard chemotherapy is challenging with sub-optimal results. Recent clinical reports of durable, objective responses from adoptive transfer of anti-CD19 chimeric antigen receptor (CAR) T cells have accentuated the

gb (code pays fourni par la source)

Evaluating the Place of Interleukin-2 in the Management of Metastatic Renal Cell Cancer (MRCC) in the Era of Targeted Therapy

Manon Evans, Shien Chow, Victoria Galvis, Robin J. Leach et autres

gb (code pays fourni par la source)

High-Dose Interleukin-2 (Hd Il2) Armed with Pathology-Based Selection Criteria: a Real Option in Treatment of Metastatic Renal Cell Carcinoma (Mrcc) After Targeted Therapy

Shien Chow, Victoria Galvis, Manon Evans, Kitty Chan et autres

gb (code pays fourni par la source)

Tolerability of epirubicin, oxaliplatin, and capecitabine chemotherapy in advanced esophagogastric cancer.

C. C. Rigby, Manon Evans, Kevin G. Chan, Andrea Spencer-Shaw et autres

e15078 Background: Oesophago-gastric cancer is the fifth commonest malignancy in the UK, and its incidence is rising. Less than 30% of patients at diagnosis are suitable for curative treatment. Randomised data supports the use of palliative chemotherapy to reduce cancer related symptoms …

gb (code pays fourni par la source)

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection

Shien Chow, Manon Evans, Victoria Galvis, R. H. Leach et autres

Meeting abstracts Despite the advent of targeted therapies, mRCC remains difficult to treat with limited prospect of cure. HD-IL2 is the only agent consistently capable of achieving durable long-term remissions. Shablak et al have previously reported improved outcomes in patients prospectively

gb (code pays fourni par la source)

Availability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the Christie

Manon Evans, Yvonne Summers, Paul Taylor, Margaret Harris et autres

gb (code pays fourni par la source)

The management of recurrent VTE in cancer patients receiving therapeutic anticoagulation: the use of dual anticoagulant therapy combined with an IVC filter

Arvind R Pillai, Adebayo Olujohungbe, Manon Evans, Norman J Main et autres

Recurrent venous thromboembolism (VTE) occurs frequently in cancer patients, yet there is little published literature to guide clinicians in the management of these patients who are already receiving therapeutic anticoagulation. We report two patients with progressive solid malignancies who presented with recurrent …

gb (code pays fourni par la source)